Abdel-Hady Algharably E, Beige J, Kreutz R, Bolbrinker J
Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Pharmacogenomics J. 2018 Apr;18(2):227-231. doi: 10.1038/tpj.2017.14. Epub 2017 Apr 18.
The genetic rs12917707-G>T variant in uromodulin (UMOD) has been associated with renal function, chronic kidney disease and hypertension with the minor T-allele showing a protective effect. Hypertension and nephrotoxicity are adverse effects of chronic cyclosporine treatment. We tested whether UMOD rs12917707-T in donor kidneys associates with long-term graft survival in 393 Caucasian patients with stable graft function for more than 10 weeks after kidney transplantation treated with a cyclosporine-based maintenance therapy (mean graft survival 9 years). Presence of the donor T-allele had no effect on blood pressure, serum creatinine 1 year after transplantation, and on number of acute graft rejections during the first year. No significant effect on overall graft survival was observed in Kaplan-Meier analysis (P=0.65). In death-censored adjusted multivariate analysis, presence of donor T-allele associated with a significant lower hazard ratio of 0.67 (95% confidence interval: 0.46-0.97, P=0.05) for graft loss. This protective effect of the donor T-allele on graft loss observed in multivariate adjusted analysis justifies further investigations including patients treated with similar or other immunosuppressive regimens.
尿调节蛋白(UMOD)基因的rs12917707 - G>T变异与肾功能、慢性肾病和高血压有关,次要的T等位基因具有保护作用。高血压和肾毒性是慢性环孢素治疗的不良反应。我们在393例接受基于环孢素维持治疗(平均移植存活9年)且移植肾功能稳定超过10周的白种人肾移植患者中,检测供体肾中UMOD rs12917707 - T是否与长期移植存活相关。供体T等位基因的存在对移植后1年的血压、血清肌酐以及第一年急性移植排斥反应的次数均无影响。在Kaplan - Meier分析中未观察到对总体移植存活有显著影响(P = 0.65)。在死亡删失调整多变量分析中,供体T等位基因的存在与移植肾丢失的风险比显著降低相关,风险比为0.67(95%置信区间:0.46 - 0.97,P = 0.05)。在多变量调整分析中观察到的供体T等位基因对移植肾丢失的这种保护作用,证明有必要进一步开展研究,纳入接受类似或其他免疫抑制方案治疗的患者。